Ticker
ADPT

Price
9.85
Stock movement up
+0.47 (5.01%)
Company name
Adaptive Biotechnologies Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Marknadsvärde
1.41B
Ent-värde
1.59B
Pris/omsättning
8.38
Pris/bok
2.89
Direktavkastning
-
Utdelningens tillväxt
-
Tillväxt år
-
FCF-utbetalning
-
Efterföljande P/E
-
Fremtidig P/E
-
PEG
-
EPS-tillväxt
-
1 års avkastning
-44.66%
3 års avkastning
-31.01%
5 års avkastning
-
10 års avkastning
-
Senast uppdaterad: 2023-02-02

UTDELNING

ADPT Betalar inte utdelning

UTVÄRDERING

Värderingsvillkor

Loading...
Data om värderingsgrad
Efterföljande P/E-
Pris till OCF-
Pris till FCF-
Pris till EBITDA-
EV i förhållande till EBITDA-

Värdering (Försäljning/Bokfört värde)

Loading...
Värderingsdata (försäljning/bokfört värde)
Pris till omsättning8.38
Pris till eget kapital2.89
EV i förhållande till försäljning9.45

EKONOMI

Per aktie

Loading...
Data per aktie
Nuvarande aktiemängd143.01M
EPS (TTM)-1.55
FCF per aktie (TTM)-1.61

Resultaträkning

Loading...
Uppgifter om resultaträkningen
Intäkter (TTM)168.04M
Bruttovinst (TTM)112.36M
Rörelseintäkter (TTM)-222.60M
Nettoresultat (TTM)-221.46M
EPS (TTM)-1.55
EPS (1 år framåt)-1.31

Marginaler

Loading...
Marginer-data
Bruttomarginal (TTM)66.87%
Rörelsemarginal (TTM)-132.47%
Vinstmarginal (TTM)-131.79%

Balans

Loading...
Skapa ett gratis konto eller logga in för att komma åt det här diagrammet
Uppgifter om balansräkningen
Kontanter217.55M
Nettofordringar26.55M
Summa omsättningstillgångar564.38M
Goodwill118.97M
Immateriella tillgångar7.26M
Materiella anläggningstillgångar0.00
Summa tillgångar884.21M
Leverantörsskulder4.16M
Kortfristig/kortfristig långfristig skuld109.05M
Summa kortfristiga skulder104.02M
Summa skulder396.39M
Eget kapital487.81M
Materiella anläggningstillgångar netto361.61M

Kassaflöde

Loading...
Skapa ett gratis konto eller logga in för att komma åt det här diagrammet
Uppgifter om kassaflöde
Kassaflöde från den löpande verksamheten (TTM)-207.75M
Investeringar (TTM)23.05M
Fritt kassaflöde (TTM)-230.80M
Utbetald utdelning (TTM)0.00

Finansiella intäkter

Loading...
Skapa ett gratis konto eller logga in för att komma åt det här diagrammet
Uppgifter om finansiella intäkter
Avkastning på eget kapital-45.40%
Avkastning på tillgångar-25.05%
Avkastning på investerat kapital-44.62%
Kontantavkastning på investerat kapital-46.50%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Uppgifter om aktiekurs
Öppning9.69
Dagens högsta10.08
Daglig låg9.65
Daglig volym1.23M
Den högsta någonsin67.74
1 års analytikeruppskattning13.00
Beta1.10
EPS (TTM)-1.55
Utdelning per aktie-
Ex-div datum-
Nästa datum för resultatpresentation14 Feb 2023

Potential på nackdelen

Loading...
Negativa potentiella data
ADPTS&P500
Nuvarande prisfall från toppnotering-85.46%-12.75%
Högsta prisfallet-90.76%-56.47%
Datum för högsta fall14 Oct 20229 Mar 2009
Genomsnittligt fall från topp-48.98%-11.49%
Genomsnittlig tid till ny topp57 days13 days
Maxtid till ny topp512 days1805 days
UPPLYSNINGAR OM FÖRETAG
ADPT (Adaptive Biotechnologies Corp) company logo
Marknadsvärde
1.41B
Kategori av marknadsvärde
Small-cap
Beskrivning: __________
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Anställda
858
Investerarrelationer
-
SEC-inlämningar
Verkställande direktör
Chad Robins
Land
USA
By
Seattle
Typ av aktie
Common stock
CCC-status
-
Utdelningsfrekvens
-
EVENEMANG OCH PRESENTATIONER
EvenemangPresentationer
Loading...
FÖRSTÅ VERKSAMHETEN
Loading...
NYHETER OM FÖRETAGET
Alla nyheterPressmeddelanden
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
30 januari 2023
SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
23 januari 2023
Capella Space, a leading American satellite manufacturer and Earth observation company, today announced it has closed $60 million in growth equity financing from the U.S. Innovative Technology Fund ("...
10 januari 2023
SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
27 december 2022
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
20 december 2022
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-makingMore than 30 clonoSEQ-related abstracts to be presented at the m...
10 december 2022
SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of...
5 december 2022
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepointsAdaptive now accepts blood samples from DLBCL patients in Streck®...
1 december 2022
SEATTLE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
21 november 2022
>95% of patients who had an MRD test describe that MRD testing helped inform treatment decisions or brought comfort in their treatment journey85% of surveyed patients have heard of MRD testing, yet on...
21 november 2022
Nästa sida